Xtacy Therapeutics (TSE:XTCY) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Xtacy Therapeutics Corp. has announced changes to its Board of Directors, with Vanni Barbon joining as a Director and the new Audit Chair, bringing a wealth of experience in banking and public markets. The company expressed gratitude to Ashleigh Vogstad for her service as she steps down, and CEO Meris Kott anticipates continued advice from her. Xtacy Therapeutics focuses on wellness consumer products, including psychedelics and healthcare-related targets.
For further insights into TSE:XTCY stock, check out TipRanks’ Stock Analysis page.